Praxis Precision Medicines Inc reports results for the quarter ended June 30 - Earnings Summary

Praxis Precision Medicines

04/08/2025 14:32

Praxis Precision Medicines Inc PRAX.OQ reported a quarterly adjusted loss of $3.31​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.74.  The mean expectation of twelve analysts for the quarter was for a loss of $3.30 per share. Wall Street expected results to range from $-3.96 to $-2.93 per share.

Reported revenue was zero​; analysts expected $145.46 thousand.

Praxis Precision Medicines Inc's reported EPS for the quarter was a loss of $3.31​.

The company reported a quarterly loss of $71.13 million.

Praxis Precision Medicines Inc shares had risen by 28.6% this quarter and lost 29.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 0.3% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Praxis Precision Medicines Inc is $82.50, about 34.4% above its last closing price of $54.09

This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-3.30
-3.31
Missed
Mar. 31 2025
-3.20
-3.29
Missed
Dec. 31 2024
-2.85
-2.94
Missed
Sep. 30 2024
-1.99
-2.75
Missed